The Functional Architecture of Personalized & Precision Medicine (PPM) Driven by Innovative Strategies to Secure the Clinical Impact and Implementation to Cancer Management: Brief Comments

Authors

  • Natalia Andronova Institute for Global Health Moscow State University for Food Industry (MGUPP), Russia
  • Boris Kobrinskii Institute for Global Health Moscow State University for Food Industry (MGUPP), Russia The National Center “The Information and Management” Russian Academy of Sciences, Moscow, Russia
  • Mikhail Kovalev Sechenov University, Moscow, Russia
  • Vladimir Zemskov A. V. Vishnevsky National Medical Research Center of Surgery Moscow, Russia
  • Sofia Blokh Institute for Global Health Moscow State University for Food Industry (MGUPP), Russia N.F. Filatov Moscow Clinical Pediatric Hospital, Moscow, Russia
  • Holland Cheng Department of Molecular and Cellular Biology College of Biological Sciences, UC Davis, Davis, CA, USA
  • Aleksandr Khlynoskii Institute for Global Health Moscow State University for Food Industry (MGUPP), Russia
  • Tatiana Grishina A. I. Evdokimov Moscow State Medical & Dental University (MGMSU), Russia
  • Andrey Zemskov N. N. Burdenko Voronezh State Medical University Voronezh, Russia
  • Hiroyuki Abe International Society for Personalized Medicine (ISPM) and Abe Cancer Clinic, Tokyo, Japan
  • Steven Dooley Medical Faculty Mannheim of the University of Heidelberg, Germany
  • Noel Rose Johns Hopkins Center for Autoimmune Disease Research and PAHO/WHO Collaborating Center for Autoimmune Disorders Johns Hopkins Medical Institutions, Baltimore, MD, and Harvard Medical School, Boston, MA, USA
  • Veronika Medvedeva Institute for Global Health Moscow State University for Food Industry (MGUPP), Russia Sechenov University, Moscow, Russia
  • Marina Moiseyakh Institute for Global Health Moscow State University for Food Industry (MGUPP), Russia
  • Tatiana Grigorieva Center for Proteomics, Kazan Federal University, Kazan, Russia
  • Sergey Suchkov Institute for Global Health, Moscow State University for Food Industry (MGUPP), Russia A. I. Evdokimov Moscow State Medical & Dental University (MGMSU), Russia EPMA (European Association for Prediction Prevention and Personalized Medicine), Brussels, EU New York Academy of Sciences, USA Personalized Medicine Coalition, Washington, DC, US Medical Faculty Mannheim of the University of Heidelberg, Germany

DOI:

https://doi.org/10.14738/jbemi.95.13230

Abstract

The medicine of the XXI century is Personalized & Precision Medicine (PPM), by protecting and preserving human health throughout the life. Creating and maintaining a high level of public health and thus the wellness is a priority in the health sector. In this regard, an upgraded model of healthcare service, which includes the philosophy, principles and armamentarium of PPM and aimed at identifying the disorder at its early (subclinical) stage, is being created and set up. PPM focuses on predictive and preventive measures that contribute to the development of individualized strategies for managing a healthy lifestyle that stabilize morbidity rates and can help to improve the working capacity of the population. Against the background of the development of PPM, there was an explosion and the evolution of the concept of biomarkers (specific bioindicators), whose combinations have been being studied, and their effectiveness and efficacy as working resources were being evaluated.

References

Suchkov S.V. «Personalized & Precision Medicine as a New Model of the Healthcare Services», V Russian Congress of Laboratory Medicine, September 12, 2019

T.A. Bodrova, D.S Kostyushev, E.N. Antonova, Sh Slavin, D.A. Gnatenko, M.O. Bocharova, M. Legg, P. Pozzilli and S.V Suchkov (2012) «Introduction into PPPM as a new paradigm of public health service: an integrative view», EPMA Journal 3 (16): 3-16.

Yadav BS, Tripathi V. Recent Advances in the System Biology-based Target Identification and Drug Discovery. Curr Top Med Chem. 2018;18(20):1737-1744. doi: 10.2174/1568026618666181025112344. PMID: 30360719.

Gupta PK. Single-molecule DNA sequencing technologies for future genomics research. Trends Biotechnol. 2008 Nov;26(11):602-11. doi: 10.1016/j.tibtech.2008.07.003. Epub 2008 Aug 21. PMID: 18722683.

Katsanis SH, Katsanis N. Molecular genetic testing and the future of clinical genomics. Nat Rev Genet. 2013 Jun;14(6):415-26. doi: 10.1038/nrg3493. PMID: 23681062; PMCID: PMC4461364.

Schildcrout, J.S. et al A prognostic model based on readily available clinical data enriched a pre-emptive pharmacogenetic testing program. J. Clin. Epidemiol. 72, 107–115 (2016)

Looße C, Swieringa F, Heemskerk JWM, Sickmann A, Lorenz C. Platelet proteomics: from discovery to diagnosis. Expert Rev Proteomics. 2018 Jun;15(6):467-476. doi: 10.1080/14789450.2018.1480111. Epub 2018 Jun 8. PMID: 29787335.

Mezzanotte L, van 't Root M, Karatas H, Goun EA, Löwik CWGM. In Vivo Molecular Bioluminescence Imaging: New Tools and Applications. Trends Biotechnol. 2017 Jul;35(7):640-652. doi: 10.1016/j.tibtech.2017.03.012. Epub 2017 May 10. PMID: 28501458.

Rowe SP, Pomper MG. Molecular imaging in oncology: Current impact and future directions. CA Cancer J Clin. 2022 Jul;72(4):333-352. doi: 10.3322/caac.21713. Epub 2021 Dec 13. PMID: 34902160; PMCID: PMC9189244.

Trivizakis, E. et al Artificial intelligence radiogenomics for advancing precision and effectiveness in oncologic care (Review). Int. J. Oncol. 57, 43–53 (2020).

Topol, E. J. High-performance medicine: the convergence of human and artificial intelligence. Nat. Med. 25, 44–56 (2019).

Wang DC, Wang X. Discovery in clinical and translational medicine. Clin Transl Med. 2021 Oct;11(10):e568. doi: 10.1002/ctm2.568. PMID: 34709762; PMCID: PMC8521278.

Bravo-Merodio L, Acharjee A, Russ D, Bisht V, Williams JA, Tsaprouni LG, Gkoutos GV. Translational biomarkers in the era of precision medicine. Adv Clin Chem. 2021;102:191-232. doi: 10.1016/bs.acc.2020.08.002. Epub 2020 Oct 3. PMID: 34044910.

Prasad V, Fojo T, Brada M. Precision oncology: origins, optimism, and potential. Lancet Oncol. 2016 Feb;17(2):e81-e86. doi: 10.1016/S1470-2045(15)00620-8. PMID: 26868357.

Laganà A. The Architecture of a Precision Oncology Platform. Adv Exp Med Biol. 2022;1361:1-22. doi: 10.1007/978-3-030-91836-1_1. PMID: 35230680.

Downloads

Published

2022-11-01

How to Cite

Andronova, N., Kobrinskii, B., Kovalev, M., Zemskov, V., Blokh, S., Cheng, H., … Suchkov, S. (2022). The Functional Architecture of Personalized & Precision Medicine (PPM) Driven by Innovative Strategies to Secure the Clinical Impact and Implementation to Cancer Management: Brief Comments. British Journal of Healthcare and Medical Research, 9(5), 375–393. https://doi.org/10.14738/jbemi.95.13230

Issue

Vol. 9 No. 5 (2022): British Journal of Healthcare and Medical Research

Section

Original Articles

License

Copyright (c) 2022 Natalia Andronova, Tatiana Grigorieva, Marina Moiseyakh, Veronika Medvedeva, Noel Rose, Steven Dooley, Hiroyuki Abe, Andrey Zemskov, Tatiana Grishina, Aleksandr Khlynoskii, Holland Cheng, Sofia Blokh, Vladimir Zemskov, Mikhail Kovalev, Boris Kobrinskii, Sergey Suchkov

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Most read articles by the same author(s)